We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Extends Convalescent Plasma Guidance an Additional Three Months
FDA Extends Convalescent Plasma Guidance an Additional Three Months
The FDA has updated its final guidance on the use of convalescent plasma in COVID-19 treatment and clinical trials, extending its enforcement to Feb. 28, 2021.